Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Perindopril arginine; Indapamide
Les Laboratoires Servier
C09BA; C09BA04
Perindopril arginine; Indapamide
2.5/0.625
Film-coated tablet
Product subject to prescription which may be renewed (B)
ACE inhibitors and diuretics; perindopril and diuretics
Marketed
2007-05-11
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT COVERSYL ARGININE PLUS 2.5MG/0.625MG FILM-COATED TABLETS perindopril arginine/indapamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Coversyl Arginine Plus 2.5mg/0.625mg is and what it is used for 2. What you need to know before you take Coversyl Arginine Plus 2.5mg/0.625mg 3. How to take Coversyl Arginine Plus 2.5mg/0.625mg 4. Possible side effects 5. How to store Coversyl Arginine Plus 2.5mg/0.625mg 6. Contents of the pack and other information 1. WHAT COVERSYL ARGININE PLUS 2.5MG/0.625MG IS AND WHAT IT IS USED FOR Coversyl Arginine Plus 2.5mg/0.625mg is a combination of two active ingredients, perindopril and indapamide. It is an anti-hypertensive and is used in the treatment of high blood pressure (hypertension) in adults. Perindopril belongs to a class of medicines called ACE inhibitors. These work by widening the blood vessels, which makes it easier for your heart to pump blood through them. Indapamide is a diuretic. Diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only causes a slight increase in the amount of urine produced. Each of the active ingredients reduces blood pressure and they work together to control your blood pressure. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE COVERSYL ARGININE PLUS 2.5MG/0.625MG DO NOT TAKE COVERSYL ARGININE PLUS 2.5MG/0.625MG - if you are allergic to perindopril or any other ACE inhibitor, or to indapamide or any other sulphonamides o Read the complete document
Health Products Regulatory Authority 12 July 2022 CRN00CNLG Page 1 of 19 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Coversyl Arginine Plus 2.5mg/0.625mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 1.6975 mg perindopril corresponding to 2.5 mg perindopril arginine and 0.625 mg indapamide. Excipient with known effect: 74.455 mg lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White, rod shaped film-coated tablet with an embossed line on both faces. The scoreline is not intended for breaking the tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Coversyl Arginine Plus 2.5mg/0.625mg is indicated in essential hypertension in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The usual dose isone Coversyl Arginine Plus 2.5mg/0.625mg film-coated tablet per day as a single dose, preferably to be taken in the morning and before a meal. If blood pressure is not controlled after one month of treatment, the dose can be doubled_._ Special populations _Elderly (see section 4.4)_ Treatment should be started at the normal dose of one Coversyl Arginine Plus 2.5mg/0.625mg film-coated tablet per day. _Renal impairment (see section 4.4)_ In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated. In patients with moderate renal impairment (creatinine clearance 30-60 ml/min), the maximum dose should be one tablet of Coversyl Arginine Plus 2.5mg/0.625mg per day. In patients with creatinine clearance greater than or equal to 60 ml/min, no dose modification is required. Usual medical follow-up will include frequent monitoring of creatinine and potassium. _Hepatic impairment (see sections 4.3, 4.4 and 5.2) _ In severe hepatic impairment, treatment is contraindicated. In patients with moderate hepatic impairment, no dose modification is required. _Paediatric population_ The safety and efficacy of perindopril arginine/indapamide in the paediatric popul Read the complete document